A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00000887|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : May 22, 2012
The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will also look at how long these drugs stay in the blood.
ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their babies. However, better treatments are needed to further reduce these chances and to better suit the treatment needs of mothers and their children. Taking a combination of anti-HIV drugs during pregnancy may be an answer.
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections Pregnancy||Drug: Nelfinavir mesylate Drug: Lamivudine Drug: Zidovudine||Phase 1|
Despite the dramatic reduction of perinatal HIV transmission by the administration of ZDV to mother and infant, new and more potent strategies are needed to further reduce perinatal transmission and better suit the diverse treatment needs of these patients. Initiation of triple antiretroviral combinations during gestation, particularly combinations that include drugs that cross the placenta such as 3TC, may be the most effective in reducing maternal virus load to its lowest levels prior to delivery.
Women receive nelfinavir plus 3TC plus ZDV antepartum (Study Day 0 until onset of active labor) through postpartum (after cord clamped to 12 weeks). [AS PER AMENDMENT 10/28/97: If patient presents in active labor with less than 1 hour to delivery time, the institutional protocol for ZDV infusion during labor should be followed.] [AS PER AMENDMENT 1/26/99: For maternal dosing, one Combivir tablet bid can be substituted for the individual formulation of 3TC and ZDV. For mothers who receive Combivir during the antepartum period, Combivir is held during labor and delivery, and the separate formulations of ZDV and 3TC are used. Patients who prematurely discontinue study treatment should continue to be followed on study for the duration of the study.] Full pharmacokinetic sampling is performed 10 to 15 days after start of therapy [AS PER AMENDMENT 2/7/00: 10 to 15 days after study entry for women currently taking nelfinavir] and again 5 to 6 weeks after delivery. A maternal blood sample and cord blood sample is collected at birth for analysis of nelfinavir concentrations. Maternal HIV RNA in plasma is monitored throughout the study. Cervicovaginal secretions are collected at entry, late gestation, and postpartum to assess the presence of HIV. A single pharmacokinetics sample is collected with each cervicovaginal secretion. Serial CD4/CD8 activation markers are measured in women during gestation and postpartum. Infants receive nelfinavir plus 3TC plus ZDV beginning approximately 12 hours following birth and continuing for 6 weeks. After birth, several blood samples are collected from the infant for determination of washout kinetics of nelfinavir. Full pharmacokinetics sampling is performed 5 to 8 days post birth and 5 to 6 weeks following multiple doses. Pharmacokinetic samples are analyzed on the first six mother-infant pairs and dosing may be adjusted accordingly for the next cohort. Agouron has agreed to make nelfinavir available to all interested study participants for a period of 6 months after the study via the patient assistance program.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||24 participants|
|Official Title:||A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant Women and Their Infants|
|Actual Study Completion Date :||July 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000887
|United States, California|
|Usc La Nichd Crs|
|Los Angeles, California, United States, 90033|
|United States, Louisiana|
|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic|
|New Orleans, Louisiana, United States, 701122699|
|Tulane/LSU Maternal/Child CRS|
|New Orleans, Louisiana, United States, 70112|
|United States, Maryland|
|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases|
|Baltimore, Maryland, United States, 212874933|
|United States, Massachusetts|
|HMS - Children's Hosp. Boston, Div. of Infectious Diseases|
|Boston, Massachusetts, United States, 021155724|
|United States, North Carolina|
|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases|
|Chapel Hill, North Carolina, United States, 27710|
|United States, Pennsylvania|
|St. Christopher's Hosp. for Children|
|Philadelphia, Pennsylvania, United States, 191341095|
|Study Chair:||Yvonne Bryson|
|Study Chair:||Mark Mirochnick|
|Study Chair:||Alice Stek|